Thomas Woiwode

Thomas Woiwode has been with Versant Ventures since 2002, serving as a Venture Partner since 2011 and a Managing Director since 2014. Mr. Woiwode has served in a number of operating roles over this time, most recently as the Chief Operating Officer of Okairos, a biopharmaceutical company developing genetic vaccines for major infectious diseases. He led the process that culminated in the sale of Okairos to GlaxoSmithKline for $325M. Prior to his role with Okairos, Mr. Woiwode co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding Chief Business Officer for three biotech companies created within Versant: Flexion (public), Synosia (public, merged with BioTie), and Amira (acquired by Bristol-Myers Squibb for up to $475M). Prior to his role as a Venture Partner, he was an Associate at Versant Ventures and served on the boards of Antipodean, Metabolex and Saegis. Mr Woiwode was a research scientist at XenoPort before joining Versant. He earned his PhD in Organic Chemistry as an NSF Fellow at Stanford University and graduated summa cum laude with a BA in English and received the Departmental Citation for his B.S. in Chemistry from UC Berkeley.

Mr. Woiwode currently serves on the boards of Annapurna, Anokion, Audentes, CRISPR, Gritstone, Kanyos Bio, and Therachon.